$3.45
0.29% today
Nasdaq, Nov 26, 12:03 am CET
ISIN
US3596161097
Symbol
FULC
Sector
Industry

Fulcrum Therapeutics Inc Stock News

Neutral
Seeking Alpha
13 days ago
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Financial Officer Iain Fraser - Senior Vice President, Early Development Patrick Horn - Chief Medical Officer Conference Call Participants Matthew Biegler - Oppenheimer Dae Gon Ha - Stifel Edward Tentho...
Neutral
GlobeNewsWire
14 days ago
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Stifel Healthcare Conference in New York City on November...
Neutral
GlobeNewsWire
20 days ago
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2024 financial results will be released on Wednesday, November 13, 2024, before the U.S. fin...
Neutral
GlobeNewsWire
about 2 months ago
CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the ...
Negative
GuruFocus
about 2 months ago
On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 3,605,932 shares in Fulcrum Therapeutics Inc (FULC, Financial), a clinical-stage biopharmaceutical company. This move reduced FMR LLC (Trades, Portfolio)'s holdings in the company to 1,724,014 shares, marking a notable shift in its investment strategy.
Neutral
GlobeNewsWire
2 months ago
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of t...
Negative
Invezz
3 months ago
Fulcrum Therapeutics Inc. (NASDAQ: FULC) saw its stock plunge 65% on Thursday after announcing that its late-stage trial for losmapimod, a treatment for facioscapulohumeral muscular dystrophy (FSHD), failed to meet its primary endpoint. This significant setback has led the biotech company to halt further development of the drug for FSHD, causing its stock to nosedive.
Neutral
GlobeNewsWire
3 months ago
― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ―

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today